ArticleJournal of cellular and molecular medicine2025
Astragalus Polysaccharide Enhances O-GlcNAcylation Through OGT to Improve Intervertebral Disc Degeneration in Rats.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-Technique Integration Identifies O-GlcNAc Transferase in Fibroblast-Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ubiquitination in intervertebral disc degeneration: from mechanisms to potential therapeutic strategies.Journal of orthopaedic translation · 2026Review
- Astragalus Polysaccharide Enhances O-GlcNAcylation Through OGT to Improve Intervertebral Disc Degeneration in Rats.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Astragalus polysaccharides (APS) are a crucial bioactive component known for their various pharmacological properties. Abnormal O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) is noted in cases of intervertebral disc degeneration (IVDD). Nonetheless, it remains uncertain whether APS regulates the process of O-GlcNAcylation associated with IVDD. We employed molecular docking, cycloheximide chase assay, immunohistochemistry, and immunoprecipitation to investigate APS-mediated OGT/O-GlcNAcylation regulation of Nrf2. The effects of APS and its role in promoting the O-GlcNAcylation of Nrf2 in IVDD through both in vivo and in vitro studies are discussed. In vitro investigations demonstrated an increase in the levels of OGT and O-GlcNAcylation in nucleus pulposus cells (NPCs) following exposure to tert-butyl hydroperoxide (TBHP). APS further facilitated improvements in OGT expression and O-GlcNAcylation processes, restoring the viability of NPCs inhibited by TBHP and promoting the synthesis of collagen II and aggrecan, while reducing apoptosis. Mechanistically, APS promotes the expression of OGT by targeting it. Furthermore, O-GlcNAcylation mediated by OGT stabilizes the expression of Nrf2 via the ubiquitin-proteasome pathway. Rescue experiments indicated that the disruption of either OGT or Nrf2 expression negated the protective role of APS on NPCs. Ultimately, both in vitro and in vivo studies indicated that APS significantly enhanced OGT expression and O-GlcNAcylation, which subsequently improved Nrf2 expression and contributed to the alleviation of IVDD in rats. APS promotes O-GlcNAcylation through OGT, thereby stabilizing the expression of Nrf2, which in turn contributes to the improvement of IVDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.